Vaccinations in children

TriHiBit (DTaP/Hib) combination products should not be used for primary immunization but can be used as boosters following any Hib vaccine in children aged >12 months. [Pg.571]

Heilmann, C. et al., Reduced antibody responses to vaccinations in children exposed to polychlorinated biphenyls. PLOS Medicine, 3, 1352, 2006.. [Pg.45]

Rosenthal, P. Cost-effectiveness of hepatitis A vaccination in children, adolescents, and adults. Hepatology 2003 37 44-51... [Pg.453]

Jacinto S, Cuenca R. Aluminum phagocytosis in quadriceps muscle following vaccination in children relationship to macrophagic myofasciitis. Pediatr Dev Pathol... [Pg.104]

In a paper dealing mainly with indications for the use of hepatitis vaccine, the data on the hepatitis A vaccines most widely used, HAVRIX (manufactured by Glaxo SmithKline) and VAQTA (manufactured by Merck), have been summarized (1). The data are based on prelicensure clinical trials and worldwide follow-up reports. No serious adverse effects have been attributed to hepatitis A vaccines. In children who received HAVRIX, soreness (15%) and induration (4%) at the injection site, feeding problems (8%), and headaches (4%) have been the most frequently observed adverse effects. In children who received VAQTA, the most common adverse effects were pain (19%), tenderness (17%), and warmth (9%) at the injection site. The reported frequencies were similar to the frequencies reported with hepatitis B vaccines. [Pg.1600]

There is a controversy about the safety of MMR vaccine in children with adverse reactions to egg. Investigating the vaccine produced by Merck Sharpe Dohme (virus grown in chicken fibroblasts), some did not detect egg protein (126). However, using a competitive ELISA others detected 74 pg of ovalbumin per ml of the MMR vaccine produced by MSD (127). This extremely low amount of ovalbumin appears to be unlikely to provoke allergic reactions. The results of a study carried out in 15 children with egg-positive skin results confirmed the view that the MMR vaccine does not contain enough egg protein to cause reactions (128). [Pg.2219]

Vernacchio L, Neufeld EJ, MacDonald K, Kurth S, Murakami S, Hohne C, King M, Molrine D. Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease. J Pediatr 1998 133(2) 275-8. [Pg.2876]

Halsey NA, Spika JS, Lum GM, Schiffman GS, Lauer BA. Adverse reactions to pneumococcal polysaccharide vaccine in children. Pediatr Infect Dis 1982 l(l) 34-6. [Pg.2877]

Herzog C, Metcalfe IC, Schaad UB (2002) Virosome influenza vaccine in children. Vaccine 20(Suppl 5) B24-B28... [Pg.27]

Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immuno-genicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group (see comments). Pediatr Infect Dis 1 2000 19 187-195. [Pg.1940]

Gruber WC. The role of live influenza vaccines in children. Vaccine 2002 20(suppl 2) S66-73. [Pg.1962]

Fuchshuber A, Kuhnemund O, Keuth B, et al. Pneumococcal vaccine in children and young adults with chronic renal disease. Neph Dial Transplant 1996 11 468-473. [Pg.2249]

Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med 1998 338 1405-1412. [Pg.2249]

Duca P, Del Pont JM, D Agostino D. Successful immune response to a recombinant hepatitis B vaccine in children after livertransplantation.JP6 c zd rGa5 ro6 A7fero/A wfr (2001) 32,168-70. [Pg.1065]

A very thoroughly investigated interaction, the weight of evidence being that no adverse interaction normally occurs with any type of influenza vaccine in children, adults or the elderly. Even so, bearing in mind the occasional and unexplained reports of an interaction it would seem pmdent to monitor the effects of concurrent use (for nausea headaches, palpitations), although problems are very unlikely to arise now that purer vaccines are available (see Mechanism ). Note that any rise in theophylline levels is likely to be transient. [Pg.1184]

Barton M, Finkelstein Y, Opavsky MA, Ito S, Ho T, Ford-Jones LE, Taylor G, Benson L, Gold R. Eosinophilic myocarditis temporally associated with conjugate meningococcal C and hepatitis B vaccines in children. Pediatr Infect Dis J 2008 27 831-5. [Pg.665]

Kienast AK, Mentze D, Hoeger PH. Nico-lau s syndrome induced by intramuscular vaccinations in children report of seven patients and review of the literature. Clin Exp Dermatol 2008 33 555-8. [Pg.665]

The influenza vaccine in children wifh inborn errors of metabolism [60 ]. [Pg.472]

Domachowske JB, Pankow-Culot H, Bautista M, Feng Y, Claeys C, Peeters M, et al. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus bivalent influenza vaccines in children aged 3-17years. J Infect Dis 2013 207(12) 1878-87. [Pg.479]

DeU Era L, Corona F, Daleno C, Scala A, Principi N, Esposito S. Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis. Vaccine 2012 30(5) 936-40. [Pg.480]

Brown, R. E., and Katz, M. (1966) Failure of antibody production to yellow fever vaccine in children with kwashiorkor. Trop. Geogr. Med, 18 125. [Pg.201]

Douglas RM, Paton JC, Duncan SJ, Flansman DJ. Antibody response to pnueu-mococcal vaccination in children younger than five years of age. J Infect Dis 1984 149 861-869. [Pg.179]

Wright PF, Cherry JD, Foy HM, et al. Antigenicity and reactogenicity of influenza A/USSR/77 virus vaccine in children—a multicentered evaluation of dosage and safety. Rev Infect Dis 1983 5 758-764. [Pg.182]

See also in sourсe #XX -- [ Pg.5 , Pg.8 , Pg.63 , Pg.557 , Pg.559 , Pg.560 , Pg.561 , Pg.562 , Pg.563 , Pg.570 , Pg.571 , Pg.572 , Pg.573 , Pg.574 ]

See also in sourсe #XX -- [ Pg.5 , Pg.8 , Pg.63 , Pg.557 , Pg.559 , Pg.560 , Pg.561 , Pg.562 , Pg.563 , Pg.570 , Pg.571 , Pg.572 , Pg.573 , Pg.574 ]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...